Trial to Assess Chelation Therapy 2 (TACT2) – Seeking women to enroll
TACT2 is an NIH funded clinical trial led by Mount Sinai Medical Center of Florida and the Duke Clinical Research Institute to assess the benefits of chelation therapy for preventing heart attacks and other cardiac events in patients who have coronary artery disease and diabetes.
This study follows a preliminary clinical trial – TACT1- which showed that chelation therapy provides a significant health boost to heart attack survivors, and particularly to those who also have diabetes.
If this clinical trial finds the same results, chelation therapy could become a therapeutic option for patients with coronary artery disease, particularly those who also have diabetes. Study sponsors would like to enroll enough women to determine if they will benefit from this therapy.
Who is eligible to participate?
Women and men who:
• Are 50 years or older
• Have had a heart attack
• Have diabetes
• Meet other eligibility criteria at the time of enrollment
Where is the study located?
The TACT2 clinical trial has sites in most states across the country. To find out if there is a testing site near you, click here.
For further information:
Download the TACT2 clinical trial brochure here.
Visit the TACT2 website, email firstname.lastname@example.org, or call (305) 674 2162.